Antiseizure Medication in Seizure Networks at Early Acute Brain Injury
Summary
The goal of this clinical trial is to explore the effect of FDA-approved antiseizure drugs in the brain connectivity patterns of severe and moderate acute brain injury patients with suppression of consciousness. The main questions it aims to answer are: * Does the antiseizure medication reduce the functional connectivity of seizure networks, as identified by resting state functional MRI (rs-fMRI), within this specific target population? * What is the prevalence of seizure networks in patients from the target population, both with EEG suggestive and not suggestive of epileptogenic activity? Participants will have a rs-fMRI and those with seizure networks will receive treatment with two antiseizure medications and a post-treatment rs-fMRI. Researchers will compare the pretreatment and post-treatment rs-fMRIs to see if there are changes in the participant's functional connectivity including seizure networks and typical resting state networks.
Timeline
- Start
- 2023-11-20
- Primary completion
- 2024-12-22
- Completion
- 2025-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosphenytoin | Small molecule | 4 mg/kg | Intravenous |
| Subject | Lacosamide | Other / unclassified | 4 mg/kg | Intravenous |
| Subject | Lacosamide | Other / unclassified | 8 mg/kg | Intravenous |
| Subject | Lacosamide | Other / unclassified | 200 mg | Intravenous |
| Subject | Lacosamide | Other / unclassified | 400 mg | Intravenous |
| Subject | Levetiracetam | Other / unclassified | 40 mg/kg | Intravenous |
| Subject | Levetiracetam | Other / unclassified | 1500 mg | Intravenous |
| Subject | Levetiracetam | Other / unclassified | 3000 mg | Intravenous |
| Subject | Phenobarbital | Unknown | 4 mg/kg | Intravenous |
| Subject | Valproate | Small molecule | 20 mg/kg | Intravenous |
| Subject | Valproate | Small molecule | 30 mg/kg | Intravenous |